Genesis Innovation Group, a Holland, Michigan-based medical device development and commercialization company, has launched a $10m venture capital fund.
Cultivate(MD) Capital Fund I will focus on investing in early stage healthcare companies, with special focus on medical device and orthopedic technologies.
Led by Rob Ball, CEO of Genesis Innovation Group and fund manager, Cultivate(MD) will be fully operational and actively seeking companies in which to invest by early 2018.
During the past four years, Genesis has focused on investments in technologies at the earliest stages, having founded a number of companies and invested at the seed and pre-seed stages. Cultivate(MD) will now expand further into this space and focus on mid- to later-stage companies and investment opportunities.
It is limited to private placements and closed to the public.
The team also includes Don Running, vice president of R&D, Matt Ahearn, VP of Finance and Operations, Dave Blue, VP of Sales and Marketing, Jeff Ondrla, VP of Supply Chain and Quality, and orthopedic surgeon and inventor, R. Sean Churchill, MD, who serves as the organizations’ Medical Director.